Table 3. Significant factors predictive of longer survival in patients treated with sorafenib.
| Characteristics | Univariate | Multivariate | ||
|---|---|---|---|---|
| RR (95% CI) | P value | RR (95% CI) | P value | |
| Sex (male) | 1.300 (0.155–10.899) | 0.809 | - | - |
| Age, yr | 0.984 (0.914–1.059) | 0.665 | - | - |
| Cirrhosis | 0.364 (0.033–4.035) | 0.410 | - | - |
| Child-Pugh class | - | - | ||
| A | 1 | 0.053 | - | - |
| B | 0.100 (0.010–1.029) | - | - | |
| High baseline AFP (> 200 ng/mL) | 0.438 (0.091–2.106) | 0.303 | - | - |
| High baseline PIVKA-II (> 125 mAU/mL) | 0.360 (0.055–2.338) | 0.284 | - | - |
| High baseline serum miR-10b-3p (Fold change > 2.2) | 0.167 (0.024–1.164) | 0.071 | 0.522 (0.045–6.032) | 0.603 |
| High baseline Serum miR-139-5p (Fold change > 0.5) | 2.700 (0.057–14.372) | 0.244 | - | - |
| MVI | 0.073 (0.011–0.487) | 0.007 | 0.038 (0.003–0.482) | 0.012 |
| Metastasis | 4.000 (0.730–21.838) | 0.109 | - | - |
RR = relative risk, CI = confidence interval, AFP = alpha-fetoprotein, PIVKA-II = protein induced by vitamin K absence/antagonist-II, MVI = macrovascular invasion.